Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer United States Business Strategies

In Brief

This article was originally published in The Tan Sheet

  • News

Executive Summary

Perrigo divests personal hygiene assets; P&G sues whitening strip private labeler; Purimune contamination prompts Baby Move recall; FDA sounds alarm on Oto-Ease recall; more news In Brief.

You may also be interested in...



P&G Crest Whitestrips Patents Repel ‘Indefiniteness’ Challenge

P&G prevails in U.S. district court arguing that three private-label tooth-whitening strip firms infringed three off its patents for Crest Whitestrips. The defendants plan to appeal the ruling against their motion that two of P&G’s patents are invalid.

P&G Crest Whitestrips Patents Repel ‘Indefiniteness’ Challenge

P&G prevails in U.S. district court arguing that three private-label tooth-whitening strip firms infringed three off its patents for Crest Whitestrips. The defendants plan to appeal the ruling against their motion that two of P&G’s patents are invalid.

Business & Finance News Roundup

NBTY sales flat; ProPhase legal costs climb; taxes trip Mannatech to a loss; and more business and finance news.

Table

View full table

Related Content

HBW Insight
Pink Sheet
Pink Sheet
HBW Insight
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
Consumer United States Business Strategies
Latest News

Stakeholders Gather To Discuss Pandemic Response And Next Steps

US FDA Says Confirmatory Trials Should Start Before Accelerated Approval But Is Not ‘Dogmatic’

Patient-Focused Drug Development Grants May Be Program’s ‘Most Significant’ Accomplishment

Lecanemab Data On Benefit In Alzheimer’s Might Satisfy FDA – But What About Medicare?

See All
UsernamePublicRestriction

Register

PS105890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By